Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Oct;19(4):307-310.
doi: 10.1007/s10689-020-00186-1. Epub 2020 May 28.

Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer

Affiliations
Case Reports

Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer

Pia Alhopuro et al. Fam Cancer. 2020 Oct.

Abstract

Germline mutations in the BRCA1 and BRCA2 genes cause hereditary breast and ovarian cancer syndrome (HBOC). Mutations in these genes are usually inherited, and reports of de novo BRCA1/2 mutations are rare. To date, only one patient with low-level BRCA1 mutation mosaicism has been published. We report on a breast cancer patient with constitutional somatic mosaicism of a BRCA2 mutation. BRCA2 mutation c.9294C>G, p.(Tyr3098Ter) was detected in 20% of reads in DNA extracted from peripheral blood using next-generation sequencing (NGS). The BRCA2 mutation was subsequently observed at similar levels in normal breast tissue, adipose tissue, normal right fallopian tube tissue and ovaries of the patient, suggesting that this mutation occurred early in embryonic development. This is the first case to report constitutional mosaicism for a BRCA2 mutation and shows that BRCA2 mosaicism can underlie early-onset breast cancer. NGS for BRCA1/2 should be considered for patients whose tumors harbor a BRCA1/2 mutation and for individuals suggestive of genetic predisposition but without a family history of HBO.

Keywords: BRCA1; BRCA2; Breast cancer; De novo; Mosaicism; Next-generation sequencing.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Sequencing analysis of the patient’s blood sample. a NGS reads and b Sanger sequencing confirmation of the NGS data showing the BRCA2 mutation c.9294C>G in mosaic form

References

    1. Lalloo F, Evans DG. Familial breast cancer. Clin Genet. 2012;82:105–114. doi: 10.1111/j.1399-0004.2012.01859.x. - DOI - PubMed
    1. Valencia OM, Samuel SE, Viscusi RK, Riall TS, Neumayer LA, Aziz H. The role of genetic testing in patients with breast cancer: a review. JAMA Surg. 2017;152:589–594. doi: 10.1001/jamasurg.2017.0552. - DOI - PubMed
    1. Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo MA, Scott RJ, Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop T, Easton D, Benitez J, King MC, Ponder BA, Weber B, Devilee P, Borg A, Narod SA, Goldgar D. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet. 1998;62:1381–1388. doi: 10.1086/301885. - DOI - PMC - PubMed
    1. Friedman E, Efrat N, Soussan-Gutman L, Dvir A, Kaplan Y, Ekstein T, Nykamp K, Powers M, Rabideau M, Sorenson J, Topper S. Low-level constitutional mosaicism of a de novoBRCA1 gene mutation. Br J Cancer. 2015;112:765–768. doi: 10.1038/bjc.2015.14. - DOI - PMC - PubMed
    1. Renaux-Petel M, Charbonnier F, Théry J, Fermey P, Lienard G, Bou J, Coutant S, Vezain M, Kasper E, Fourneaux S, Manase S, Blanluet M, Leheup B, Mansuy L, Champigneulle J, Chappé C, Longy M, Sévenet N, Paillerets BB, Guerrini-Rousseau L, Brugières L, Caron O, Sabourin J, Tournier I, Baert-Desurmont S, Frébourg T, Bougeard G. Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. J Med Genet. 2018;55:173–180. doi: 10.1136/jmedgenet-2017-104976. - DOI - PubMed

Publication types